Suppression of Spry1 reduces HIF1α-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma
Abstract Background About 50% of cutaneous melanoma (CM) harbors the activating BRAFV600 mutation which exerts most of the oncogenic effects through the MAPK signaling pathway. In the last years, a number of MAPK modulators have been identified, including Spry1. In this context, we have recently dem...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13046-025-03289-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850087420745220096 |
|---|---|
| author | Barbara Montico Giorgio Giurato Roberto Guerrieri Francesca Colizzi Annamaria Salvati Giovanni Nassa Jessica Lamberti Domenico Memoli Patrizia Sabatelli Marina Comelli Arianna Bellazzo Albina Fejza Lucrezia Camicia Lorena Baboci Michele Dal Bo Alessia Covre Tuula A. Nyman Alessandro Weisz Agostino Steffan Michele Maio Luca Sigalotti Maurizio Mongiat Eva Andreuzzi Elisabetta Fratta |
| author_facet | Barbara Montico Giorgio Giurato Roberto Guerrieri Francesca Colizzi Annamaria Salvati Giovanni Nassa Jessica Lamberti Domenico Memoli Patrizia Sabatelli Marina Comelli Arianna Bellazzo Albina Fejza Lucrezia Camicia Lorena Baboci Michele Dal Bo Alessia Covre Tuula A. Nyman Alessandro Weisz Agostino Steffan Michele Maio Luca Sigalotti Maurizio Mongiat Eva Andreuzzi Elisabetta Fratta |
| author_sort | Barbara Montico |
| collection | DOAJ |
| description | Abstract Background About 50% of cutaneous melanoma (CM) harbors the activating BRAFV600 mutation which exerts most of the oncogenic effects through the MAPK signaling pathway. In the last years, a number of MAPK modulators have been identified, including Spry1. In this context, we have recently demonstrated that knockout of Spry1 (Spry1KO) in BRAFV600-mutant CM led to cell cycle arrest and apoptosis, repressed cell proliferation in vitro, and reduced tumor growth in vivo. Despite these findings, however, the precise molecular mechanism linking Spry1 to BRAFV600-mutant CM remains to be elucidated. Materials and methods Immunoprecipitation coupled to mass spectrometry was employed to gain insight into Spry1 interactome. Spry1 gene was knocked-out using the CRISPR strategy in the BRAF-mutant cell lines. Transmission electron microscopy was used to assess the relationship between Spry1 expression and mitochondrial morphology. By using in vitro and in vivo models, the effects of Spry1KO were investigated through RNA-sequencing, quantitative real-time PCR, Western blot, and immunofluorescence analyses. The Seahorse XF24 assay allowed real-time measurement of cellular metabolism in our model. Angiogenic potential was assessed through in vitro tube formation assays and in vivo CD31 staining. Results Spry1 was mainly located in mitochondria in BRAFV600-mutant CM cells where it interacted with key molecules involved in mitochondrial homeostasis. Spry1 loss resulted in mitochondrial shape alterations and dysfunction, which associated with increased reactive oxygen species production. In agreement, we found that nuclear hypoxia-inducible factor-1 alpha (HIF1α) protein levels were reduced in Spry1KO clones both in vitro and in vivo along with the expression of its glycolysis related genes. Accordingly, Ingenuity Pathway Analysis identified “HIF1α Signaling” as the most significant molecular and cellular function affected by Spry1 silencing, whereas the glycolytic function was significantly impaired in Spry1 depleted BRAFV600-mutant CM cells. In addition, our results indicated that the expression of the vascular endothelial growth factor A was down-regulated following Spry1KO, possibly as a result of mitochondrial dysfunction. Consistently, we observed a substantial impairment of angiogenesis, as assessed by the tube formation assay in vitro and the immunofluorescence staining of CD31 in vivo. Conclusions Altogether, these findings identify Spry1 as a potential regulator of mitochondrial homeostasis, and uncover a previously unrecognized role for Spry1 in regulating nuclear HIF1α expression and angiogenesis in BRAFV600-mutant CM. Significance Spry1KO profoundly impacts on mitochondria homeostasis, while concomitantly impairing HIF1α-dependent glycolysis and reducing angiogenesis in BRAF-mutant CM cells, thus providing a potential therapeutic target to improve BRAFV600-mutant CM treatment. |
| format | Article |
| id | doaj-art-76f4093565b74b528f788cdcedaadaf3 |
| institution | DOAJ |
| issn | 1756-9966 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Experimental & Clinical Cancer Research |
| spelling | doaj-art-76f4093565b74b528f788cdcedaadaf32025-08-20T02:43:13ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662025-02-0144112010.1186/s13046-025-03289-8Suppression of Spry1 reduces HIF1α-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanomaBarbara Montico0Giorgio Giurato1Roberto Guerrieri2Francesca Colizzi3Annamaria Salvati4Giovanni Nassa5Jessica Lamberti6Domenico Memoli7Patrizia Sabatelli8Marina Comelli9Arianna Bellazzo10Albina Fejza11Lucrezia Camicia12Lorena Baboci13Michele Dal Bo14Alessia Covre15Tuula A. Nyman16Alessandro Weisz17Agostino Steffan18Michele Maio19Luca Sigalotti20Maurizio Mongiat21Eva Andreuzzi22Elisabetta Fratta23Immunopathology and Cancer Biomarkers Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCSDepartment of Medicine, Surgery and Dentistry ‘Scuola Medica Salernitana’, Laboratory of Molecular Medicine and Genomics, University of SalernoImmunopathology and Cancer Biomarkers Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCSImmunopathology and Cancer Biomarkers Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCSDepartment of Medicine, Surgery and Dentistry ‘Scuola Medica Salernitana’, Laboratory of Molecular Medicine and Genomics, University of SalernoDepartment of Medicine, Surgery and Dentistry ‘Scuola Medica Salernitana’, Laboratory of Molecular Medicine and Genomics, University of SalernoImmunopathology and Cancer Biomarkers Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCSDepartment of Medicine, Surgery and Dentistry ‘Scuola Medica Salernitana’, Laboratory of Molecular Medicine and Genomics, University of SalernoCNR-Institute of Molecular Genetics “Luigi Luca Cavalli-Sforza”, Unit of BolognaDepartment of Medicine, University of UdineImmunopathology and Cancer Biomarkers Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCSMolecular Oncology Unit, Centro Di Riferimento Oncologico Di Aviano (CRO), IRCCSMolecular Oncology Unit, Centro Di Riferimento Oncologico Di Aviano (CRO), IRCCSImmunopathology and Cancer Biomarkers Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCSExperimental and Clinical Pharmacology Unit , Centro Di Riferimento Oncologico Di Aviano (CRO), IRCCSUniversity of SienaDepartment of Immunology, University of Oslo and Oslo University HospitalDepartment of Medicine, Surgery and Dentistry ‘Scuola Medica Salernitana’, Laboratory of Molecular Medicine and Genomics, University of SalernoImmunopathology and Cancer Biomarkers Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCSUniversity of SienaOncogenetics and Functional Oncogenomics Unit, Centro Di Riferimento Oncologico Di Aviano (CRO), IRCCSMolecular Oncology Unit, Centro Di Riferimento Oncologico Di Aviano (CRO), IRCCSObstetrics and Gynecology, Institute for Maternal and Child Health - IRCCS “Burlo Garofolo”Immunopathology and Cancer Biomarkers Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCSAbstract Background About 50% of cutaneous melanoma (CM) harbors the activating BRAFV600 mutation which exerts most of the oncogenic effects through the MAPK signaling pathway. In the last years, a number of MAPK modulators have been identified, including Spry1. In this context, we have recently demonstrated that knockout of Spry1 (Spry1KO) in BRAFV600-mutant CM led to cell cycle arrest and apoptosis, repressed cell proliferation in vitro, and reduced tumor growth in vivo. Despite these findings, however, the precise molecular mechanism linking Spry1 to BRAFV600-mutant CM remains to be elucidated. Materials and methods Immunoprecipitation coupled to mass spectrometry was employed to gain insight into Spry1 interactome. Spry1 gene was knocked-out using the CRISPR strategy in the BRAF-mutant cell lines. Transmission electron microscopy was used to assess the relationship between Spry1 expression and mitochondrial morphology. By using in vitro and in vivo models, the effects of Spry1KO were investigated through RNA-sequencing, quantitative real-time PCR, Western blot, and immunofluorescence analyses. The Seahorse XF24 assay allowed real-time measurement of cellular metabolism in our model. Angiogenic potential was assessed through in vitro tube formation assays and in vivo CD31 staining. Results Spry1 was mainly located in mitochondria in BRAFV600-mutant CM cells where it interacted with key molecules involved in mitochondrial homeostasis. Spry1 loss resulted in mitochondrial shape alterations and dysfunction, which associated with increased reactive oxygen species production. In agreement, we found that nuclear hypoxia-inducible factor-1 alpha (HIF1α) protein levels were reduced in Spry1KO clones both in vitro and in vivo along with the expression of its glycolysis related genes. Accordingly, Ingenuity Pathway Analysis identified “HIF1α Signaling” as the most significant molecular and cellular function affected by Spry1 silencing, whereas the glycolytic function was significantly impaired in Spry1 depleted BRAFV600-mutant CM cells. In addition, our results indicated that the expression of the vascular endothelial growth factor A was down-regulated following Spry1KO, possibly as a result of mitochondrial dysfunction. Consistently, we observed a substantial impairment of angiogenesis, as assessed by the tube formation assay in vitro and the immunofluorescence staining of CD31 in vivo. Conclusions Altogether, these findings identify Spry1 as a potential regulator of mitochondrial homeostasis, and uncover a previously unrecognized role for Spry1 in regulating nuclear HIF1α expression and angiogenesis in BRAFV600-mutant CM. Significance Spry1KO profoundly impacts on mitochondria homeostasis, while concomitantly impairing HIF1α-dependent glycolysis and reducing angiogenesis in BRAF-mutant CM cells, thus providing a potential therapeutic target to improve BRAFV600-mutant CM treatment.https://doi.org/10.1186/s13046-025-03289-8Spry1HIF1αCutaneous melanomaBRAFMitochondria |
| spellingShingle | Barbara Montico Giorgio Giurato Roberto Guerrieri Francesca Colizzi Annamaria Salvati Giovanni Nassa Jessica Lamberti Domenico Memoli Patrizia Sabatelli Marina Comelli Arianna Bellazzo Albina Fejza Lucrezia Camicia Lorena Baboci Michele Dal Bo Alessia Covre Tuula A. Nyman Alessandro Weisz Agostino Steffan Michele Maio Luca Sigalotti Maurizio Mongiat Eva Andreuzzi Elisabetta Fratta Suppression of Spry1 reduces HIF1α-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma Journal of Experimental & Clinical Cancer Research Spry1 HIF1α Cutaneous melanoma BRAF Mitochondria |
| title | Suppression of Spry1 reduces HIF1α-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma |
| title_full | Suppression of Spry1 reduces HIF1α-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma |
| title_fullStr | Suppression of Spry1 reduces HIF1α-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma |
| title_full_unstemmed | Suppression of Spry1 reduces HIF1α-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma |
| title_short | Suppression of Spry1 reduces HIF1α-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma |
| title_sort | suppression of spry1 reduces hif1α dependent glycolysis and impairs angiogenesis in braf mutant cutaneous melanoma |
| topic | Spry1 HIF1α Cutaneous melanoma BRAF Mitochondria |
| url | https://doi.org/10.1186/s13046-025-03289-8 |
| work_keys_str_mv | AT barbaramontico suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT giorgiogiurato suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT robertoguerrieri suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT francescacolizzi suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT annamariasalvati suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT giovanninassa suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT jessicalamberti suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT domenicomemoli suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT patriziasabatelli suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT marinacomelli suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT ariannabellazzo suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT albinafejza suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT lucreziacamicia suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT lorenababoci suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT micheledalbo suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT alessiacovre suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT tuulaanyman suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT alessandroweisz suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT agostinosteffan suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT michelemaio suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT lucasigalotti suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT mauriziomongiat suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT evaandreuzzi suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma AT elisabettafratta suppressionofspry1reduceshif1adependentglycolysisandimpairsangiogenesisinbrafmutantcutaneousmelanoma |